This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

J&J Buy of Aragon Deals a Blow to Medivation

Medivation now has a formidable competitor for prostate cancer therapy.

Winners And Losers in CLL at ASCO '13
Winners And Losers in CLL at ASCO '13

06/10/13 - 07:00 AM EDT

Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged.

Aveo's Future Depends on Triple-Negative Breast Cancer

Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.

Page 1 of 1
< Previous
Next >
Top Rated Stocks Top Rated Funds Top Rated ETFs